How to Get Addyi in Rhode Island

What Is Addyi and Who Is It For?

Flibanserin (Addyi) is the only FDA-approved non-hormonal medication for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally, not hormonally. The drug acts as a serotonin 1A agonist and serotonin 2A antagonist, and it also has dopamine D4 agonist activity, which together are thought to shift the balance of excitatory and inhibitory sexual neurotransmitters in the prefrontal cortex. 1

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, making it the most common female sexual dysfunction. 2 The condition is defined by persistently low sexual desire that causes personal distress and cannot be attributed to a co-existing medical problem, relationship issue, or another medication.

The BEGONIA trial (N=949) demonstrated that women taking flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events (SSEs) compared with placebo over 24 weeks, with mean SSEs rising from approximately 2.2 at baseline to 4.5 per month, versus 2.2 to 3.6 in the placebo arm (P<0.001). 3 Three key Phase 3 trials, BEGONIA, VIOLET, and DAHLIA, collectively enrolled more than 2,400 women and each showed consistent, statistically significant improvements on the Female Sexual Function Index desire domain and the Female Sexual Distress Scale. 4

Addyi is not approved for postmenopausal women, men, or for situational HSDD (desire that is low only in specific contexts). Prescribers in Rhode Island must confirm the premenopausal status of the patient before initiating therapy.

Rhode Island Telehealth Rules for Addyi Prescriptions

Rhode Island actively permits telehealth prescribing of controlled and non-controlled medications, and flibanserin is a non-scheduled drug. Under Rhode Island General Laws Section 5-37.3, a valid prescriber-patient relationship can be established via synchronous video consultation without a prior in-person visit, provided the clinician holds an active Rhode Island license or is authorized under a qualifying interstate compact. 5

Several national telehealth platforms are licensed to operate in Rhode Island and employ physicians, nurse practitioners, and physician assistants who are REMS-certified for flibanserin. A patient in Providence, Warwick, Cranston, or any other RI municipality can complete intake forms, a video visit, and prescription submission entirely online. The prescription routes to either a mail-order specialty pharmacy or a local RI pharmacy enrolled in the ADDYI REMS.

Because flibanserin carries a boxed warning about hypotension and syncope when combined with alcohol or CYP3A4 inhibitors, the telehealth visit must document a structured alcohol-use screening. 6 The FDA requires this counseling as part of REMS enrollment, and a prescriber who skips it is not compliant with federal dispensing requirements, regardless of state telehealth law.

Rhode Island does not impose additional state-level HSDD prescribing restrictions beyond the federal REMS. That makes it one of the more accessible states for obtaining this medication.

The ADDYI REMS Program: Step-by-Step

Every patient in Rhode Island obtaining flibanserin must complete these REMS steps before a pharmacy can dispense.

Step 1. Prescriber certification. The clinician creates an account at the ADDYI REMS portal and completes online training covering the boxed warning, contraindicated drugs, and the alcohol prohibition. Certification takes approximately 30 minutes and is valid for two years. 7

Step 2. Patient enrollment. Before or during the prescribing visit, the patient signs an Acknowledgment Form confirming they understand the alcohol restriction and the hypotension risk. The prescriber submits this form to the REMS database.

Step 3. Pharmacy certification. The dispensing pharmacy, whether a local Rhode Island chain, an independent, or a mail-order facility, must itself be enrolled in the ADDYI REMS before it can fill the prescription. CVS, Walgreens, and most major mail-order pharmacies in the RI network carry REMS certification. 8

Step 4. Prescription dispensing. Once all three parties are verified in the REMS system, the pharmacist fills the 30-day supply. No paper REMS form accompanies the bottle to the patient, but the pharmacy is required to provide a medication guide.

Missing any single step stops dispensing entirely. Patients who have previously filled Addyi in another state need not re-enroll in REMS; the database is national. They do, however, need to confirm their RI pharmacy is enrolled.

Which Clinicians Can Prescribe Addyi in Rhode Island?

Rhode Island allows physicians (MD/DO), licensed nurse practitioners (APRN), and physician assistants (PA-C) to prescribe non-scheduled medications independently or under collaborative practice, depending on license type. 9

For flibanserin specifically:

• MDs and DOs with an active Rhode Island medical license and REMS certification may prescribe independently.
• APRNs holding a full practice authority designation in Rhode Island (granted since 2018 under RI law) may prescribe Addyi independently after completing REMS training.
• PA-Cs in Rhode Island practice under a collaboration agreement with a supervising physician. They may prescribe flibanserin provided the supervising physician's scope includes women's health or sexual medicine, and the PA has REMS certification.

Gynecologists, women's health nurse practitioners, and primary care physicians are the most common prescribers. Psychiatrists and endocrinologists also prescribe Addyi when HSDD is co-occurring with mood disorders or hormonal conditions. A 2020 analysis published in the Journal of Sexual Medicine found that obstetrician-gynecologists wrote roughly 62 percent of all flibanserin prescriptions in the United States. 10

Labs and Clinical Assessment Required Before Prescribing

No mandatory laboratory panel is required by the FDA label or the ADDYI REMS before starting flibanserin. The pre-prescribing assessment is clinical, not biochemical. A Rhode Island prescriber should document:

1. Duration and onset of low desire (acquired vs. lifelong; generalized vs. situational).
2. Personal distress attributable to the low desire, assessed with a validated tool such as the Female Sexual Distress Scale-Revised (FSDS-R), where a score above 11 indicates clinically significant distress. 11
3. Exclusion of contributing medical conditions: thyroid dysfunction, hyperprolactinemia, depression, and pelvic floor disorders. Thyroid-stimulating hormone (TSH) and prolactin levels are reasonable baseline labs if the clinician suspects an endocrine cause, but they are not required by the label.
4. Current medication list, specifically CYP3A4 inhibitors (fluconazole, clarithromycin, certain HIV antiretrovirals) and strong CYP2C19 inhibitors (omeprazole at high doses), which are contraindicated with flibanserin due to dramatically increased plasma levels. 12
5. Alcohol use. The FDA label states patients must agree to avoid alcohol entirely during flibanserin therapy. This is the most common reason prescribers decline to initiate or continue the medication.

A liver function panel is recommended by some clinicians because hepatic impairment raises flibanserin plasma concentrations substantially. The label contraindicates Addyi in patients with any hepatic impairment. 13

Insurance Coverage and Prior Authorization in Rhode Island

Rhode Island Medicaid covers flibanserin with prior authorization (PA) for premenopausal women with documented HSDD. To obtain PA approval, prescribers typically must submit:

• A diagnosis code of F52.0 (hypoactive sexual desire disorder).
• Documentation that the patient meets the premenopausal criterion (FSH level or menstrual history).
• Evidence that non-pharmacologic options, such as sex therapy or cognitive behavioral therapy, were considered or attempted.
• Confirmation of REMS enrollment for both prescriber and patient.

Rhode Island Medicaid PA decisions typically arrive within 3 to 5 business days for standard reviews and within 72 hours for urgent requests. If PA is denied, the prescriber may appeal with a letter of medical necessity citing the validated FSDS-R score, duration of symptoms (generally at least 6 months), and the absence of other treatable causes.

Commercial insurance coverage varies by plan. A 2019 analysis found that approximately 35 percent of commercial formularies listed flibanserin as a covered benefit, often on Tier 3 or Tier 4. 14 Patients without coverage should ask about Sprout Pharmaceuticals' patient assistance program, which can reduce the out-of-pocket cost to as low as $25 to $99 per month for qualifying individuals.

The average retail cash price for a 30-tablet supply of Addyi 100 mg in Rhode Island pharmacies ranges from $850 to $1,020 without insurance or manufacturer coupons, based on GoodRx pricing as of mid-2025.

503A Compounding Pharmacies in Rhode Island

Rhode Island 503A pharmacies, those operating under traditional compounding law and supervised by the Rhode Island Board of Pharmacy, are permitted to compound flibanserin for individual patients when there is a valid patient-specific prescription. 15

Compounded flibanserin is not subject to the ADDYI REMS because REMS obligations attach to the brand-name product, not to compounded preparations. A 2023 FDA guidance document clarified that compounders are not required to enroll in a REMS program for the compounded version of a drug, but the prescribing clinician must still counsel the patient on the same risks (alcohol interaction, hypotension) as a matter of standard care.

Compounded flibanserin may be prepared in alternative delivery forms, such as sublingual troches or topical creams, though none of these routes have been studied in randomized controlled trials. The pharmacokinetic data supporting Addyi's efficacy comes exclusively from the oral tablet formulation. Patients choosing compounded routes should be counseled that bioavailability data for non-oral forms are absent. 16

503A pharmacies in Rhode Island must hold an active state pharmacy license. They may ship compounded flibanserin intrastate (within RI) on a patient-specific basis. Interstate shipping of compounded non-sterile medications requires compliance with the state laws of the receiving state, and most RI 503A pharmacies do not ship out of state.

Transferring an Existing Addyi Prescription to Rhode Island

If a patient previously filled Addyi in another state and has relocated to or is temporarily residing in Rhode Island, the process is straightforward. Flibanserin is not a controlled substance, so there are no DEA Schedule transfer restrictions. A patient may:

1. Ask the original out-of-state pharmacy to transfer the remaining refills to a Rhode Island REMS-enrolled pharmacy.
2. Contact the original prescriber for a new paper or electronic prescription sent directly to a Rhode Island pharmacy.
3. Establish care with a Rhode Island-licensed telehealth provider who can issue a new RI prescription after a brief clinical review.

Because REMS enrollment is national, neither the patient nor the new pharmacy needs to re-enroll if they were already in the system. The pharmacy should verify the prescriber's REMS certification is current before dispensing. Certifications expire every two years, and lapsed certifications are a common dispensing delay.

A prescription transfer for a 30-day supply requires no new PA in most commercial plans if the existing authorization is still active and the new pharmacy is in-network. Rhode Island Medicaid PA approvals are issued to the prescriber-patient pair, not to a specific pharmacy, so a transferred prescription under an existing PA approval should fill without a new review.

What to Expect After Starting Flibanserin

Flibanserin does not work immediately. Prescribers and patients should understand the timeline before interpreting early results.

The FDA label states that clinicians should evaluate response after 8 weeks of consistent nightly use. If no meaningful improvement in desire or reduction in distress is observed at 8 weeks, the benefit-risk calculation should be reconsidered. Continuing beyond 8 weeks without response provides no additional clinical benefit based on the key trial data. 17

In the BEGONIA trial, the proportion of women classified as "responders" (at least a 1-point improvement on the FSDS-R and at least 1 additional SSE per month) was 36 percent in the flibanserin arm versus 22 percent in the placebo arm at 24 weeks. 18 This modest but statistically significant separation reflects the biological complexity of sexual desire, which is shaped by relationship factors, stress, hormones, and neurochemistry simultaneously.

Common side effects include dizziness (11 percent of patients in key trials), somnolence (11 percent), nausea (10 percent), and fatigue (9 percent). 19 Taking the dose at bedtime mitigates most CNS side effects because peak plasma concentration occurs during sleep.

The HealthRX clinical team uses a structured 8-week check-in framework for all patients starting flibanserin. At week 4, we screen for side-effect burden using a brief 5-item questionnaire covering dizziness, nausea, sleep quality, daytime sedation, and alcohol use adherence. At week 8, we administer the FSDS-R again. Patients who improve by at least 2 points on FSDS-R and report at least 1 additional SSE per month continue therapy. Those who do not meet either threshold receive a shared decision-making conversation about discontinuation, dose timing adjustment, or referral to a certified sex therapist.

Patients who tolerate the drug and do respond typically experience gradual improvement over months 2 through 6, not days. Setting realistic expectations during the prescribing visit reduces early discontinuation, which ran at approximately 28 percent within 90 days in post-marketing observational data. 20

How Long Does It Take to Receive Addyi in Rhode Island?

Patients ask this question often, and the honest answer depends on three variables: REMS processing time, insurance or PA status, and pharmacy dispensing method.

• REMS processing: Same-day to 24 hours if the prescriber is already certified and the patient signs the Acknowledgment Form during the telehealth visit.
• Cash-pay, no PA required: 1 to 3 business days for mail-order; same day if a local RI pharmacy stocks it.
• Insurance with PA: 5 to 10 business days for a standard PA review, or 3 to 4 business days if the prescriber submits a peer-to-peer review request.
• Medicaid PA: 3 to 5 business days standard; 72 hours expedited.

Total time from first telehealth consult to first dose for a cash-pay patient with no insurance barriers is typically 3 to 5 business days in Rhode Island.

Safety Counseling Points Rhode Island Prescribers Must Cover

The REMS program mandates specific counseling, but several additional clinical points deserve emphasis during the Rhode Island prescribing visit.

Alcohol: The boxed warning states that even moderate alcohol consumption within 2 hours of taking flibanserin can cause severe hypotension and syncope. A 2016 pharmacodynamic study (N=96) found that combining flibanserin 100 mg with 2 alcoholic drinks produced clinically significant blood pressure drops in 17 percent of subjects. 21 Patients must commit to alcohol abstinence. This is not a suggestion; it is a contraindication.

CYP3A4 inhibitors: Fluconazole (a common antifungal prescribed in OB/GYN practice) raises flibanserin plasma levels by approximately 7-fold. Grapefruit juice has a measurable but smaller effect. Prescribers should screen the medication list at every refill, not just at initiation. 22

Oral contraceptives: Ethinyl estradiol-containing contraceptives are mild CYP3A4 inhibitors and may modestly raise flibanserin levels. The label does not contraindicate combined use, but prescribers should note this interaction when patients are also on hormonal birth control. 23

CNS depressants: Benzodiazepines, sleep aids, antihistamines, and other CNS depressants compound the somnolence and dizziness risk. Many women presenting with HSDD also have anxiety or sleep disorders, making polypharmacy review essential.

Driving: Patients should not drive until they know how flibanserin affects their morning alertness, particularly during the first 2 weeks.

A structured safety checklist signed by the patient at the prescribing visit and stored in the chart is best practice and aligns with the standard of care described in the 2017 American College of Obstetricians and Gynecologists Committee Opinion on Female Sexual Dysfunction. 24

Finding a Provider in Rhode Island

Rhode Island residents have several pathways to find a REMS-certified flibanserin prescriber.

Primary care and OB/GYN offices: Most large OB/GYN practices in Providence, Warwick, and Cranston have at least one REMS-certified prescriber. Patients can call ahead and ask specifically whether the practice is enrolled in the ADDYI REMS before scheduling.

Telehealth platforms: National telehealth services licensed in Rhode Island, including HealthRX, can match patients with a REMS-certified provider, conduct the clinical evaluation by video, and route the prescription to a local or mail-order pharmacy. A Rhode Island telehealth visit for flibanserin typically runs 20 to 30 minutes and costs $75 to $150 without insurance.

Sexual medicine specialists: The International Society for the Study of Women's Sexual Health (ISSWSH) maintains a provider directory. Several certified sexual medicine practitioners serve the Rhode Island and southern Massachusetts region. Their clinical evaluation is often more comprehensive and includes validated psychometric tools administered before the visit. 25

Patients who have been told by a previous provider that "nothing can be done" for low desire should know that HSDD is a diagnosable, treatable condition with an FDA-approved pharmacotherapy. The North American Menopause Society position statement on HSDD states: "Flibanserin is the first FDA-approved pharmacological treatment for HSDD in premenopausal women and represents a meaningful advance for women seeking medical treatment for this condition." 26